News - Metabolics, Eisai

Filter

Current filters:

MetabolicsEisai

Popular Filters

Report: Obesity therapy market forecast to reach $8.4 billion by 2022

Report: Obesity therapy market forecast to reach $8.4 billion by 2022

20-11-2013

Due to the launches of several novel drugs during the next decade, the obesity therapeutics market will…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNovo NordiskPharmaceuticalVictoza

Eisai to double Belviq sales force by December

Eisai to double Belviq sales force by December

15-10-2013

Eisai’s US subsidiary will increase its force for the obesity drug Belviq to around 400 representatives…

Arena PharmaceuticalsBelviqEisaiManagementMarkets & MarketingMetabolicsNorth AmericaPharmaceutical

Eisai's launch plan for obesity drug Belviq in USA enters consumer phase

16-09-2013

The US launch campaign by Japanese drug major Eisai (TYO: 4523) of the weight-loss drug Belviq (lorcaserin)…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceutical

It's official: "obesity is a disease," says AMA

20-06-2013

The American Medical Association at its annual meeting this week adopted a policy that recognizes obesity…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaRegulationVivus

Arena/Eisai's Belviq at last to launch in the USA

07-06-2013

USA-based Arena Pharmaceuticals (Nasdaq: ARNA) says that its long-awaited weight loss drug Belviq (lorcaserin)…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceutical

Arena and Eisai finally get DEA scheduling for obesity drug Belviq

08-05-2013

The long wait to get obesity drug Belviq (lorcaserin) to the US market, where it was approved by the…

Arena PharmaceuticalsBelviqEisaiMetabolicsNorth AmericaPharmaceuticalRegulation

Arena Pharma pulls EU application for Belviq; posts 1st-qtr results

06-05-2013

As part of an update on its activities and first-quarter financial results report, USA-based Arena Pharmaceutical…

Arena PharmaceuticalsBelviqEisaiEuropeFinancialMetabolicsPharmaceuticalRegulation

Eureka moment: US FDA approves first new obesity drug in 13 years

28-06-2012

After several years of investigation, and a rejection by the US regulator, the Food and Drug Administration…

Arena PharmaceuticalsBelviqEisailorcaserinMetabolicsNorth AmericaPharmaceuticalRegulation

Arena Pharma updates on lorcaserin filings in EU and USA

27-03-2012

San Diego, USA-based Arena Pharmaceuticals (Nasdaq: ARNA) revealed yesterday that the European Medicines…

Arena PharmaceuticalsEisaiEuropelorcaserinLorquessMetabolicsNorth AmericaPharmaceuticalRegulation

FDA updates on obesity drug candidates

11-01-2012

There have been two pieces of positive news coming out of the US Food and Drug Administration this week…

Arena PharmaceuticalsEisailorcaserinLorquessMetabolicsNorth AmericaPharmaceuticalQnexaRegulationVivus

Arena files complete response on lorcaserin

05-01-2012

In another attempt to gain approval for its obesity drug candidate that was turned down by US regulators…

Arena PharmaceuticalsEisailorcaserinLorquessMetabolicsNorth AmericaPharmaceuticalRegulationResearch

Arena and Eisai release data on obesity drug candidate lorcaserin to be used in CRL response

03-08-2011

USA-based Arena Pharmaceuticals (Nasdaq: ARNA) and Japanese partner Eisai (TYO: 4523) announced the completion…

Arena PharmaceuticalsEisailorcaserinMetabolicsPharmaceuticalResearch

Back to top